ISRCTN14012970进行中（未招募）4 期
Efficacy of dapagliflozin compared to furosemide for controlling blood pressure in uncontrolled hypertension with subclinical fluid retention in chronic kidney disease
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- 干预性
入排标准
- 性别
- All
入选标准
- Current inclusion criteria as of 12/04/2024:
- Age from 18 years old
- Chronic kidney disease (GFR-EPI 20-60 ml/min/1.73m2)
- Uncontrolled hypertension with fluid retention detected by bioimpedance
- Previous inclusion criteria:
- Age from 18 years old
- Chronic kidney disease (GFR-EPI 20-60 ml/min/1.73m2)
- Resistant hypertension
排除标准
- Current exclusion criteria as of 12/04/2024:
- Patient receiving diuretics or SGLT2i
- Uncontrolled HT with euvolemic status
- Life expectancy <12 months (principal investigator’s judgement)
- Living-donor transplant scheduled within the next 12 months
- Cardiovascular disease (dilated cardiomyopathy, valvular heart disease)
- Active infection
- Current active malignancy
- Known HIV or active hepatitis B or C
- Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range
- Pregnancy or breastfeeding
- Subject has any kind of disorder that compromises their ability to informed consent and/or to comply with study procedures
- Previous exclusion criteria:
- Life expectancy less than 12 months
- Living-donor transplant scheduled within the next 12 months
- Cardiovascular disease (dilated cardiomyopathy, valvular heart disease)
- Active infection
- Current active malignancy
- Known HIV or active hepatitis B or C
- Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range
- Pregnancy or breastfeeding
- Subject has any kind of disorder that compromises their ability to informed consent and/or to comply with study procedures
研究者
标识符
- 注册编号
- ISRCTN14012970
- 其他研究编号
- il known, IRB8866
日期
- 研究完成日期
- (2年前)
- 最近更新
- (2年前)
监管与共享
- 是否有结果
- 是